- NewsCategory：
- All Company news Industry news
common83One result
-
1031
Gotham Therapeutics Establishes Advanceγ÷&d Oncology Profiling Cascade with Pr₩★oQinase to Progress its Portfolio of Epitβ€←↕ranscriptomic Drug Candidates
Gotham Therapeutics Establishes Advanced OΩφα ncology Profiling Cascade with Pro婶Qinase to Progress its ∞δ÷Portfolio of Epitranscrip♦×tomic Drug CandidatesWEDNESDAY, OCTOBER 30, ♥ ₽2019Gotham Therapeutics, a biotechnology comφ≥pany developing a novel drug cl±∏ ass targeting RNA-modifying proteins₩₽±, and ProQinase, an ear↕αly stage drug-discovery company, r÷ecently acquired by Malve ¶rn/PA-based Reaction Biology Corp.≤♠∏✘, today announced that they have establ₹ished an array of advanced biochemical and ce☆∞llular assays to characterize epitranscrip <¥tomic-directed compounα✘₩™ds.“Establishing tailored target engage>™£ment, cell biology, "γphenotypic, and in-vi♣≤vo assays to evaluate compounds originatin>σg from our three most advaλ☆±nced epitranscriptomic programs in paralle¶↕l is a crucial next step εσ™to develop our broad pipeline towards the cl₩←¶<inic,” said Dr. Gerhard Mül♥αler, Chief Scientific Officer of G÷♠otham Therapeutics. “$↑↓"By pursuing the full rang✔∑←£e of the reader-writer-™®πeraser continuum, we are able to focus on targe≠<™¶ts with the most compelling links to disease and ∏•advance those programs in tandem.”±±“Combining our high proficie©Ωncy in providing customized solutions as earl®δ☆®y stage drug-discover♦λ✘£y services, including tailor-made biochemical ✘ '≥and cell-based assays, with Gotham↕¶’s expertise in epitranscriptomics, we ÷< were able to establish in a very short time•' a set of customized enzymatic and cellular >•assays for compounds add£♣ressing three different mRNA-•™modifying targets,” said D← r. Sebastian Dempe, Chief Eδσ"xecutive Officer of ProQi®÷★nase. “We look forward to supporting Gotham as↕π the company advances its programs into l←↑ead optimization and to continued work<☆≤© with the Gotham team ♦≈≤assisting the company to ad→∏✘φvance its broad pipeline in aβ© time-effective manner.”In additionα✔®≈ to establishing a tailor-made profiling¥÷" cascade for compounds from its three ♥¥ most advanced programs, Gotham hβ♦as also made progress in strengthening its →♣<¶drug discovery engine and dλ♥₹"eveloping its candidate base. Gotham previousl©☆$y completed the gene-←₹εto-lead phase for its drug discovery pr÷↓oject targeting the MET ↔₽TL3/METTL14 complex andγ€ established a robust discovery process as aδφ platform for future projects. The company has a♦φlso generated a library of high♦γ-quality compounds tail₽★₹πor-made for accelerated&'∏ hit generation and hit-to-lead ex>←×pansion against large pλ§arts of the epitranscripto→∑mic target space. This lib£₩♠rary includes a collection ≠★♦εof over 2,000 analogues covering over 80 dis>¶™tinct chemotypes that will beβ÷★ used to further accelerate Gotham’s dβσλrug discovery efforts as i★←πt expands its pipeline.The ori€δginal link:https://www.phaσ→rmafocusasia.com/news/gotham-therapeutics-establi"φ→shes-advanced-oncology-profili♥↑<ng-cascade-with-proqinase-to-progress-its-port✘γfolio-of-epitranscriptomic-drug-candiφ ±¶dates2019 Asia-pacific pharm'•a IP Leader Summit: ✔♥₩http://en.zenseegroup.com/p/510934/will be held☆© in Beijing Ωλ☆₹on November 14-15, and w∑∏<>ill attract more than 500 industry experts from±ε domestic and foreigΩ₹÷n pharmaceutical companies, biotechnology♥↔ companies, governments, associations,↓& © law firms, intellectual property agenπ&δts and other companies to attend.Official☆φ™¥ registration and consultation channels:C"™®£ontact：AnnPhone: 021-65650305Emai₹∞l：Marketing@zenseegroup.comhttp:↑∑π//en.zenseegroup.com/p/510934 -
1030
Gilead and Glympse Bio Announce Sπ¥≠trategic Collaboration for Use o®>↔f Biomarker Technolog±&y in NASH Clinical Developm&×ent
Gilead and Glympse Bio Announce Stra∑ πtegic Collaboration for Use of Biomarker Tech ©¶nology in NASH Clinical Developmeφπ←₩ntTUESDAY, OCTOBER 29, 2019Gilead £ ↓Sciences Inc. and Glympse Bio, Inc., toda$δy announced that the com®₩panies have entered into a s∑£♣trategic collaboration in nonalcoholi✘×&≈c steatohepatitis (NASH) clinical development. G€♠lympse Bio’s proprietary synthetic bi φ→omarkers – bioengineered to identify stage ↑ and progression of disease as well as early d ×↑etection of treatment response – wilσσ↓l be used to determine clinical trial particip✘ δants’ stage of disease at initial s≤Ωcreening and to determine res₹"γponses to study trea>ε≠tment in Gilead’s NASH clinical program.“We are§↕δ£ excited about the opportunity to partn£♥≤£er with Glympse Bio to help informα§ our NASH development program'®,” said Mani Subramanian, MD, PhD Senior Vε★ice President, Liver Diseases, Gilead Scien₽≤₽ces. “By utilizing this innovative techn§>¥ology, we hope to better characterize thi± ≠₩s complex disease and improve our understandin§✘g of how our compounds impact disease progr✘εession.”Glympse Bio’s↓♦ ↔ proprietary technology, Glympse Inside™,§ ✘ combines synthetic biomarkers with machine lear∑αning approaches to identify the st$§∑age and monitor progression of important, ®∑↕ complex diseases such as cancer, fibrosis✘®↕∑, inflammation, and infections, in real≥&≈ time.“We are very excited about partnering with↑✔σ Gilead, a leader in drug ÷ development, to help drive earlier and mo×₽±re favorable outcomes for patients,” said C •∞aroline J Loew, President and CE±♦♠O, Glympse Bio. “Gilead’s c βommitment to developing inno<↕♣vative medicines in areas of hig≤↕☆≥h unmet medical need aligns with our mission ≠ of transforming disease detection↕✘σ and measuring treatment response£÷, all with the goal of♠↑♠ helping improve the lives of patien©÷ts.”information sou±δrce:pharma focus AsiaThe originalΩ link:https:https:https://www.pharm↓γ>afocusasia.com/news/gilead-aγ×ε×nd-glympse-bio-announce-stratΩ÷↔ egic-collaboration-for-use-of-biomarker-techno♦✔δ£logy-in-nash-clinical-development2★"₹σ019 Asia-pacific pharma IP Leader Summit:↔<http://en.zenseegroup.com/p/510934/&nbλβγ<sp;will be held in ★≠λ∏Beijing on November 14-15, $↑εand will attract more than 500 indu"Ω¥stry experts from domestic and foreign pha¶&rmaceutical companies, b∏★iotechnology companies, governments, assoλ☆ciations, law firms, intellectual proper≈Ωσ&ty agents and other companies to attend.Official ∑✘registration and consultation channels:Contact：AδγnnPhone: 021-65650305÷→Email：Marketing@zenseegro•εup.comhttp://en.zenseegroup.com/p/51✘★₩♦0934 -
1029
HistoIndex Announces Global Partner₹♣ships To Expand AI-Based Digital Pathology Pα latform
HistoIndex Announces Global Par×'tnerships To Expand AI-Based Digital Patholoφ✔≥gy PlatformMONDAY, OCTOBER 2®<8, 2019HistoIndex announces the expansion ₹ε♥★of its AI-based digital pathology plat≤∞©±form towards large-sε ¶cale NASH preclinical programs for pharmac€✘↕eutical and biotech companies↑" to achieve quantifiable and rep™ δroducible data on therapeutic response↑"s in NASH animal models, and to aγ$id CROs as well as researc♥★•h agencies in validating new models mim®"↓£icking the NASH disease.Published pε§'←reclinical studies have★≠ demonstrated the useλ≠> of HistoIndex's fully quantifiable Secondβε★< Harmonic Generation (≤αSHG) technology as a highly accu& rate stain-free method that c÷Ω an monitor the efficacy of various therapeut™∑×ic agents, by quantifying moreσσ than 450 NASH-associated↔®↕ parameters in fibrosis, inflammation₹¥, ballooning and steatosis. The information of≈γ↕ these NASH-associated parameters gath ♦™ered from the entire liver tissue, provi∞₽des comprehensive insights on the↔±← mechanism of action of t±λhe therapeutic agent. ★&; As a drug discover±₽y tool, HistoIndex's SHG-¶∏₹γenabled digital pathol≈ ¥ogy platform will allow pharmaceutical and biotec↑↑h companies to select ∞&promising lead candidate '×s for further optimization and make info≠εrmed decisions in the management of th★∑eir NASH drug development pipeline.In add ₩σition to ongoing NASH∏≈®♥ clinical trials, Hiλ>stoIndex is currently involved in mult★πiple preclinical studies, most of which a αβre conducted by major α×pharmaceutical and biotech companies, ✔Ωmedical universities, CROs and↓₹ research agencies. Notably,γ± HistoIndex has recently entered into a >¥ collaboration with the A*STAR's Genome Instit✔≠ute of Singapore (GIS) to validate their §≠in vivo and in vitro NASH models based on A$↔¥sian-centric clinical data. Say€ ™↕s Professor Patrick Tan, Exec₩ >utive Director of the Genome Institute♦♦∏ of Singapore (GIS), "At GIS, >λσwe conduct our preclinica↔¶¥§l studies on fatty liver involving dataΩΩ☆← from animal models based on patient-derived±€® transcriptomic data. T>£Ωhis has a high translational potential 'Ω as it helps us to pinpoi±<✘nt new therapeutic targets and thei↔r validation. Therefor≥↔β≥e, using a fully quantitative,<Ω reliable and objective pathological ev ₩aluation such as HistoIndex's AI-based d÷¥" igital pathology platf♣≠★orm is essential to the success ↓β¶of our efforts in therape<€φutic target discovery."HistoInd$$ex is also a partner ∞←with globally-renowned CRO, WuXi Appte↑←c, in advancing their NAφ SH preclinical programs with adv∏anced R&D and smart i®≥≠$maging analysis capabilities. Publish₹← ed study data will be£σ<ε available for discussions during networking op÷₩portunities throughout AASLD's The Liver Meeti •ng® in November 2019. €♥ "We are very excited< to extend our AI-based S δφγHG platform to preclinical studie >s to help companies with drug discovery programs εε select promising lead candidates for further≈♦φ optimization and subsequ∞✔ent clinical development," say㣧s Dr Poon Thong Yuen, Chief Exec <∏utive Officer of HistoIndπ&ex. "Our SHG image ana<$lysis platform has already been used to← analyze the efficacy of a ♦≤≥γseries of promising "✔drug candidates for NASH wit₩₩♦hin various animal modπ↔ε≥els commonly-used by the ♦±industry, and we believe these pπ✔↓$reclinical partnerships will help driv•♠£↑e the adoption of our platform significantly." φ≤information source:pharm÷←αa focus AsiaThe original link:https:https://www.Ω∑≈pharmafocusasia.com/n δews/histoindex-announces-global-par€tnerships-to-expand-ai-based-di ♣gital-pathology-platform2019 Asia-pacific "αpharma IP Leader Summit: http"∏α↔://en.zenseegroup.com/p/5109≥σα34/will be held in Beijing&≈λδ®nbsp; on November 14-15, and wβ→ill attract more than 5✘±€00 industry experts frβ♣≠ om domestic and foreign pha♠≈rmaceutical companies, biotechnology companies,₩☆ governments, associations, law firms, intellectu↑✔al property agents and other compani± ↑♥es to attend.Official r© ™egistration and consultation channels:Conta¥ βct：AnnPhone: 021-65650305Email：Marketing@zen →±seegroup.comhttp://en.zenseegroup.com/p/51093 €4 -
1028
AVROBIO Receives Orphan↓&✘-Drug Designation from the U.S. FDA for∞©♦ AVR‑RD‑02 for the Treatment of§✔σβ Gaucher Disease
AVROBIO Receives Orphaβ∞n-Drug Designation from t₽↕☆he U.S. FDA for AVR‑RD‑02 f♣±↑or the Treatment of Gaucher Disγ'∏easeFRIDAY, OCTOBER 25,₹α∞¶ 2019AVROBIO, Inc., today announced that φ÷∞the U.S. Food and Dr♥ ↔ug Administration (FD♠§ $A) has granted orphan-drug designation for the C"←↓ompany’s investigational gene ¥₩λ therapy, AVR-RD-02, for the treatment ⥕of Gaucher disease. AVR-RD-02 c≈∏₩onsists of the patient’s own hema∏×÷₩topoietic stem cells, genetically modifie♠§×d to express glucocerebrosidase (GCase), the e₽$≈nzyme that is deficient in Gaucher di∞φsease. The Company is actively recruiting in Canελada for its Phase 1/2 clinical trial of AVR-RD-≤$✘02, which seeks to evaluate the ↓↓☆safety and efficacy of the therapy÷§•♠ in patients with Type 1 Ga÷↓λγucher disease.“Under the>↔ existing standard of care, patients with Ga♠γ÷ucher disease are bound to a liπ≥<✔felong infusion schedule of enzy≤↔πme replacement therapies, ★→<and still experience painful and→∏"← progressive symptoms s• uch as debilitating muscul®α☆oskeletal pain and fatigue,” saidδ↔ Birgitte Volck, MD, PhD, President of"Ω Research and Development at♥♥≤α AVROBIO. “Orphan-drug designat↑₩≠ion recognizes the unmet need₩λ of populations with rare diseases like Gauc£γ↓™her where AVROBIO strives to t∑©♦ransform lives by addressing the underlying ¥πβ∞cause of the disease with a single dose o↔§<↓f gene therapy.”Orphan-drug designati✔∏ →on is granted by the FDA to dru"$♠✔gs and biologics which are ₩γ☆intended for the saf✔ αe and effective treatment, diagnosis ←δor prevention of rare diseases or condition→™↔s that affect fewer than 200,000 people in §σ λthe United States. Orphan-drug designatioγ≤☆≤n provides certain incentives, which may includ∞§e tax credits towards the cost of clinical trials↓β§₽ and prescription drug user fee waivers.inform€ation source:pharma focus AsiaThe∏¥×• original link:https:https:≥//www.pharmafocusasia.com/news/avrobi§$≠o-receives-orphan-drug-dε"→πesignation-from-the-u↑×εs-fda-for-avrrd02-for-the-treatmen↑∞t-of-gaucher-disease2019 Asia-pacific pharma IP©©§ Leader Summit: http://en€↔₩.zenseegroup.com/p/5∞≈10934/will be held in Beijing & ♦nbsp;on November 14-15, and will at αtract more than 500 industry exper₹♣★ts from domestic and foreign pharmaceuti$× <cal companies, biotec↓ ₹hnology companies, gγ♠overnments, associations, law fi÷'rms, intellectual property agents and other comp§βanies to attend.Official registration a¶¥ nd consultation channels:Contact：AnnPhone: 021-65α 650305Email：Marketing@zenseegroup.comhttp://£♠εen.zenseegroup.com/p/510934 -
1026
AZTherapies StrengtheΩ♦ns Neuroinflammation-Tar÷ε©≤geted Pipeline Through Acquisition of Smith The♣←∞∏rapeutics
FRIDAY, OCTOBER 25, 2019AZTherapies, I↕€↓↕nc., a biopharmaceutical company develop÷®∏ing therapeutics to extend brain ÷∑health, today announced the acquisition of Smith >Ω↔÷Therapeutics, a private biopha×★<λrmaceutical company with a sh 'ared goal of targeting neuroinflammation to§™ treat neurodegenerative disease. Smith Ther₩±•apeutics’ Founder and Chi¥£ ↑ef Executive Officer Phili♣←p Ashton-Rickardt, Ph.D., has joine§¶≈πd the senior leadership team at AZTherapies as↓✘≈♣ Senior Vice President of Iπ$mmunology. Financial teγ₹←rms of the acquisition were not disclo≈∏♦≤sed.Smith Therapeutics’ proπ€prietary research pl←∑>atform focuses on th↑<γ↑e use of modified T cells to restore a heal↔☆thy balance of inflamm₹$©atory and regulatory ce∏&★lls in the brain. To ∑≈date, Smith has successfully engineereΩ∑÷d immunosuppressive T regulatory (Tre÷ε$g) cells with Chimeric Aβ↑♣σntigen Receptors (CARs) targeti↔★ ✔ng brain glial cells. Previous research has demo ÷λ←nstrated the ability of Tregs to dampen£₽™γ microglial activity an♠βd reduce neuroinflammation×✔ in models of neurodegeneration, sugge♣₽φ♠sting their potential↓σ utility in the treatment of diseases including©δ≤ Progressive Supranuclea&π>r Palsy (PSP), Alzheimer’s disease, Parkinso♣γ∏♥n’s disease, Huntington’s disease, ✔↔→€Amyotrophic Lateral Sclerosis (AL ♥S), and others.“This acquisition represent→φ∞∞s a meaningful step forward f≈≤↑or us as we continue to strengλ£ then our leadership position in the"φ> development of therapies Ω₽ targeting neuroinflammation to stop or slow the p∑¶rogression of neurodegenerative diseases,” ∞₽∞said David R. Elmaleh, Ph.D., F≈×₽ounder, CEO, and Chairman €¶of AZTherapies. “We are e$₽xcited to be working with Philip as we add t₩his cutting-edge technology to our portfolio of♥δ± innovative programs. An est¥€♠eemed immunologist and inventoΩ'₹πr of the technology, Philip brings unparalle✘π₹led expertise to the company and we looε≤ 'k forward to advancing λδ™this CAR-Treg program further into ↑✘IND-enabling studies and into clinica≤ ☆l development as rapidlαy as possible.”Dr. Ashton-Rickardt©α commented on the acquisition and h §×is appointment: “Our≥ shared rationale of target ing neuroinflammation as the root cause • ¥of neurodegenerative disease makes this ac≈ quisition a great str✘∞↕ategic fit for us. Wi♣♥th AZTherapies’ expertise in dru ≈g development and clinical trial execution, we be'¥lieve that together, we are we₹€♦ll positioned to advance our CAR-Treg tec≥®÷hnology and fundamental↓ ly change neurodegenerative dis÷∑ease progression.”Prior to launching Smithφ™ Therapeutics in 2017, Dr. ≤¥↔Ashton-Rickardt was Chair in©§σσ Immunology at Imperial College London, V¶φ<∏isiting Professor, Brigham and Women’₽€ ✔s Hospital, Harvard Medical School, and Asso≤≈ciate Professor in the Departm≈•ent of Pathology at th♠★ ×e University of Chicago. HΩ∞'÷is work has been recognized by his peδ₩✘ers through the award of tenure from The ≥University of Chicago and by his fellow citi∏↓≥₹zens as a recipient of the Early Career Aw¥≠↓∑ard for Scientists and Engineers from P♥ ♠resident Bill Clinton. He has published more₹" than 65 peer-reviewed papers in more™₽ λ than 30 academic journals (including Cell×★, Science, Immunity, and Na★π£ture Immunology), has served"÷© as an editor for several academic ±✘journals, and has been a member of grant review λ¶♣✘boards globally. Dr. As hton-Rickardt received a $∏ B.Sc. in Biochemistry from the University of Lon✘∑₽don, King’s College with honors, a Ph.D. in M$¶✔↔olecular Biology from th☆♣e University of Edinbα≤✔urgh, and completed post-doctoral work at the Uni≠<®∞versity of Edinburgh and the Massachuset↓★ts Institute of Techn≠÷×ology in Molecular Biology and Molecul&> ar Immunology, respectively.informatiβon source:pharma• focus AsiaThe original link:httpsα&β&:https://www.pharmafocusasia.com/news/azt≥$herapies-strengthens-≤♥neuroinflammation-targeted-pipeline-th←×≤×rough-acquisition-of-smit≠©¥h-therapeutics2019 Asia-pacific pharma $>IP Leader Summit: http://en.zΩ•¶enseegroup.com/p/510934/will bδ×γe held in Beijing&nbsαγ¶p; on Novembe↔★r 14-15, and will attract more thaγγ"n 500 industry experts fro₽↔" m domestic and foreign pha♥→rmaceutical companies, biotechnolπogy companies, governments, associ♦λ ations, law firms, intellectual property agents a☆♦ €nd other companies to attend.Offici∑∞↕al registration and con®™₽¥sultation channels:Contact：AnnPhone: 021-65&δ±ε650305Email：Marketing@zenseegroup.coλ≤₹±mhttp://en.zenseegroup.com/p/510934
Contact Us
Zensee_Daystar online
© 2011-2016